Target intelligence / Profile preview

Hippocampal glucose metabolism

Molecular classification
Other
01

Overview

Hippocampal glucose metabolism refers to the collective pathways by which glucose is taken up, processed, and utilized by cells in the hippocampus, a critical brain region for memory and cognition. This process involves glucose transporters (such as GLUTs), glycolysis, oxidative phosphorylation, and astrocyte-neuron lactate shuttling, among other mechanisms. Hippocampal glucose metabolism is altered in various brain disorders, including Alzheimer’s disease (where microglia and astrocytes show characteristic metabolic changes)[1][2][4], psychosis[5], and normal aging[3]. Deficits in this process are associated with neuronal dysfunction, atrophy of hippocampal subfields, and cognitive impairment. Some experimental drugs act indirectly to modify hippocampal glucose metabolism by targeting upstream metabolic regulators, such as the enzyme IDO1 in glial cells[2][4]. This entry is not a molecular drug target or receptor, but a tissue-level metabolic phenotype/process. For specific targets, such as glucose transporters (GLUTs), metabolic enzymes (e.g., hexokinase, pyruvate dehydrogenase), or regulators (e.g., IDO1), please specify the molecule of interest.

Other names
Hippocampal metabolic activityHippocampal glucose uptakeHippocampal glycolysis
02

Mechanism of action

IDO1 inhibition restores astrocyte-derived glycolytic support (lactate production/transfer) to neurons, normalizing glucose metabolism in the hippocampus[2][4].

03

Biological functions

Brain energy metabolismSynaptic plasticityNeuronal activity supportNeuroinflammation (indirect)Memory and cognition (indirect)
04

Disease associations

Neurodegenerative diseaseAlzheimer’s diseasePsychosisCognitive declineOther
05

Interacting drugs

Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors (e.g., PF068)
06

Biomarkers

^18F-FDG PET signal in hippocampus (for glucose uptake/metabolic rate)[1]Plasma HbA1c and glycated albumin (systemic indices associated with hippocampal atrophy/deficit)[3]HOMA-IR, HOMA-β (markers of insulin resistance/secretion correlated with hippocampal volume loss)[3][5]

Beyond the preview

Go deeper on Hippocampal glucose metabolism.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hippocampal glucose metabolism.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call